Skip to main content
. Author manuscript; available in PMC: 2018 Feb 4.
Published in final edited form as: Lancet. 2016 Dec 23;389(10068):519–527. doi: 10.1016/S0140-6736(16)31594-X

Table 2.

Multivariate age-adjusted progression-free survival and overall survival

Patients (N=471)* Progression-free survival
Overall survival
HR (95% CI) p value HR (95% CI) p value
Patients given bortezomib with lenalidomide and dexamethasone (VRd group) 242 (51%) 0·73 (0·58–0·92) 0·007 0·74 (0·55–1·00) 0·048
International Staging System stage III 157 (33%) 1·58 (1·16–2·13) 0·003 2·16 (1·43–3·25) 0·0003
International Staging System stage II 184 (39%) 1·16 (0·86–1·57) 0·322 1·18 (0·77–1·81) 0·447
Intent to transplant 324 (69%) 0·98 (0·74–1·28) 0·866 0·86 (0·61–1·20) 0·371
Age ≥65 years 202 (43%) 1·32 (1·03–1·71) 0·031 1·88 (1·34–2·62) 0·0002

Data are n (%) unless otherwise stated.

*

N=471 patients with valid data for factor.